Rylander M, Nord C E, Norrby S R
Department of Clinical Microbiology, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden.
Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):919-24. doi: 10.1007/BF01963784.
The in vitro activity of the new penem derivative ALP-201 against 226 aerobic and 350 anaerobic clinical bacterial isolates was determined using agar dilution techniques. For comparison amoxicillin, cefaclor, ceftazidime, doxycycline, erythromycin, imipenem and trimethoprim/sulfamethoxazole were also tested with aerobic bacteria, and cefoxitin, chloramphenicol, clindamycin, imipenem, metronidazole and piperacillin with anaerobic bacteria. ALP-201 was found to be highly active against Escherichia coli, Klebsiella spp., Enterobacter spp., Haemophilus influenzae, Branhamella catarrhalis, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, anaerobic cocci, Propioni-bacterium acnes, Clostridium perfringens, Bacteroides fragilis, Bacteroides spp. and fusobacteria. Pseudomonas aeruginosa and Clostridium difficile were resistant to ALP-201. When tested against aerobic bacteria using a high inoculum or using the broth dilution technique, the activity of ALP-201 showed little dependence on inoculum size and the bactericidal activity was similar to the inhibitory activity. Further investigations are warranted with ALP-201, which is absorbed from the gastrointestinal tract after oral administration.
采用琼脂稀释技术测定了新型青霉烯衍生物ALP - 201对226株需氧和350株厌氧临床分离菌株的体外活性。作为比较，还对需氧菌测试了阿莫西林、头孢克洛、头孢他啶、多西环素、红霉素、亚胺培南和甲氧苄啶/磺胺甲恶唑，对厌氧菌测试了头孢西丁、氯霉素、克林霉素、亚胺培南、甲硝唑和哌拉西林。结果发现ALP - 201对大肠杆菌、克雷伯菌属、肠杆菌属、流感嗜血杆菌、卡他布兰汉菌、金黄色葡萄球菌、肺炎链球菌、化脓性链球菌、厌氧球菌、痤疮丙酸杆菌、产气荚膜梭菌、脆弱拟杆菌、拟杆菌属和梭杆菌具有高度活性。铜绿假单胞菌和艰难梭菌对ALP - 201耐药。当使用高接种量或肉汤稀释技术对需氧菌进行测试时，ALP - 201的活性对接种量大小的依赖性很小，杀菌活性与抑菌活性相似。口服后可从胃肠道吸收的ALP - 201值得进一步研究。
